Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II

Phase 2

Recruiting

• Conditions: Depression
• Interventions: Drug: Propofol; Diagnostic Test: Electroencephalography (EEG); Behavioral: Brief Behavioral Therapy for Insomnia

• Registration Number: NCT06867549
• Lead Sponsor: Washington University School of Medicine

Brief Summary

The investigators hypothesize that brief behavioral therapy and targeted propofol infusion in depressed geriatric patients will augment subsequent slow wave sleep and improve clinical and cognitive outcomes. The team will recruit 70 participants for a double-blinded placebo controlled randomized controlled trial. Two propofol infusions, 2-6 days apart, will be administered, targeting either a low propofol dose arm (minimal EEG slow waves, brain effect-site concentration 1-2 mcg/ml) or moderate dose propofol arm (maximal induction of EEG slow waves, brain effect site concentration of \>2.5 mcg/ml). The pharmacologic intervention will be paired with 3-4 sessions of Brief Behavioral Therapy for Insomnia for all participants. To minimize bias, there will be no specific gender or ethnic background consideration for enrollment. This will be a single site investigation at Washington University Medical Center.

Detailed Description

Depression in older adults is a leading cause of disability, excess mortality from suicide, and dementia. Cognitive problems and sleep disturbances are common, contributing to recurrence and poor long-term outcomes. Disrupted slow-wave sleep is at the nexus of depression and cognitive dysfunction in older adults. Novel approaches to target this core pathophysiology are lacking. This mechanistic project is designed to elucidate the relationships between TRD and sleep disturbances in older adults. Through personalized infusions targeting electroencephalographic (EEG) patterns, the investigators aim for a systematic characterization of the relationships between the propofol (dose and EEG measures) and enhancement of slow wave sleep, with associated secondary clinical and cognitive outcomes. Through the re-purposing of propofol as a therapeutic probe, this innovative proposal will establish whether EEG slow waves are a viable therapeutic target for novel antidepressant approaches.

Two BBTI sessions will be administered before the propofol infusions, with two additional sessions within 6 weeks after the 2nd infusion. The sessions will completed remotely or in person.

Propofol will be infused through a peripheral IV, with the assistance of target-controlled infusion software and pumps, with an anticipated infusion duration of 2 hours. Concurrent high-density EEG will be acquired. Participants will be discharged home after nurse monitoring and fulfillment of post-anesthetic care unit criteria.

Patients will be instructed by staff on the operation of the SOMNOmedics HST for at-home overnight sleep EEG recordings. Patients will demonstrate the ability to successfully wear the device and initiate recordings without assistance. The device, charger, tablet, and instructional materials will be provided to patients.

Overnight sleep recordings will be obtained prior to the first propofol infusion and on evenings of propofol infusions. Additionally, recordings will be obtained for up to 6 weeks after the final infusion, to evaluate persistence of restoration of sleep architecture.

Primary and secondary endpoints will be analyzed based on age, sex, time separating propofol infusions, induction of EEG measures during infusions, pharmacokinetic exposure times at varying concentrations, adherence to BBTI, and concomitant medications. Additional analyses will be based on medical comorbidity (Cumulative Illness Rating Scale Score), baseline MOCA score (23-26 for cognitively impaired) vs (26-30 for cognitively intact), age of onset of first episode of MDD (to address the importance of late-onset depression), baseline MADRS, ISI, MAPS-SR, AD8, GAD-7, or STOP-Bang.

Additionally, structure of baseline sleep (e.g. duration and proportion of total sleep time for N3 and REM) will be utilized in sub-group analysis. If high variance in SWS enhancement is observed, we could perform univariate regression analyses to evaluate for the presence of covariates driving the high variance.

Study Timeline

• Study First Submitted: 2025-02-25
• Status Verified: 2025-03
• Study Start: 2025-03-04
• Study First Submitted QC: 2025-03-04
• Last Update Submitted: 2025-03-07
• Study First Posted: 2025-03-10
• Last Update Posted: 2025-03-11
• Primary Completion: 2028-02-01
• Study Completion: 2028-04-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Age 60 or greater
• English speaking (as an interpreter will not be readily available should a participant need to convey any safety concerns during the propofol infusion sessions or require guidance on conducting at-home sleep recordings)
• Depression (non-responsive to at least one adequate trial of oral antidepressants for current episode).

Exclusion Criteria

• Presence of symptomatic coronary artery disease
• Presence of marked congestive heart failure/cardiomyopathy(NYHA > Class III, LVEF <40%, greater than mild RV systolic dysfunction)
• Prior reaction to propofol
• Resting heart rate < 50 bpm
• Treatment with Electroconvulsive therapy/Transcranial Magnetic Stimulation/vagal nerve stimulation within 6 weeks
• Body mass index > 35
• C-SSRS of 4 or greater (active suicidal ideation with some intent and with/without a specific plan)
• MoCA score < 23 (at least mild dementia)
• Schizophrenia
• Bipolar disorder
• Non-prescribed use of amphetamines, opioids, cocaine, or phencyclidine; Urine THC > 150 ng/ml
• Intake of > 14 beers/week (or equivalent)
• Anesthetic exposure in the past 4 weeks
• Concurrent use of benzodiazepines > 2 mg/day lorazepam or equivalent, trazodone > 50 mg/day, or gabapentin > 600mg/day.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Propofol infusion -moderate dose	Propofol	Serial propofol infusions to maximally and safely induce unconsciousness and EEG slow waves while minimizing burst suppression. Target brain effect-site concentrations \>2.5 mcg/ml. This will be paired with BBTI.
Propofol infusion -moderate dose	Electroencephalography (EEG)	Serial propofol infusions to maximally and safely induce unconsciousness and EEG slow waves while minimizing burst suppression. Target brain effect-site concentrations \>2.5 mcg/ml. This will be paired with BBTI.
Propofol infusion -moderate dose	Brief Behavioral Therapy for Insomnia	Serial propofol infusions to maximally and safely induce unconsciousness and EEG slow waves while minimizing burst suppression. Target brain effect-site concentrations \>2.5 mcg/ml. This will be paired with BBTI.
Propofol infusion - low dose	Propofol	Serial propofol infusions to safely induce unconsciousness while minimizing EEG slow waves and burst suppression.Target brain effect-site concentration of 1-2 mcg/ml. This will be paired with BBTI.
Propofol infusion - low dose	Electroencephalography (EEG)	Serial propofol infusions to safely induce unconsciousness while minimizing EEG slow waves and burst suppression.Target brain effect-site concentration of 1-2 mcg/ml. This will be paired with BBTI.
Propofol infusion - low dose	Brief Behavioral Therapy for Insomnia	Serial propofol infusions to safely induce unconsciousness while minimizing EEG slow waves and burst suppression.Target brain effect-site concentration of 1-2 mcg/ml. This will be paired with BBTI.

Primary Outcome Measures

Name	Time	Method
Change in SWS duration	Pre-infusion and on the nights of propofol infusions	This is the total duration of N3 averaged across infusion nights relative to baseline average. The average change in total duration of N3 infusion nights relative to baseline.

Secondary Outcome Measures

Name	Time	Method
Changes in anhedonia	Pre-infusion and up to 10 weeks after second infusion	Anhedonia: MAP-SR (primary) and SHAPS (secondary) at 1-, 3-, and 10 weeks post-infusion. Higher scores indicate worse outcomes.
Affects on sleep structure	Pre-infusion and up to 6 weeks after second infusion sleep recordings	Evaluate changes in sleep structure: Sleep: %, TST = N3 on infusion nights and weeks after infusion.
Changes in depression	Pre-infusion and up to 10 weeks after second infusion	Examine Propofol-associated changes in depression at approximately at 2-days, 1-, 3-, and 10 weeks post-infusion. (MADRS, 0-60) This assesses for changes in depression after propofol infusions. Higher scores indicate worse outcomes.
Affects on cognition (Fluid Cognition)	Pre-infusion and up to 10 weeks after second infusion	Evaluate change in Cognitive Performance on the Oxford miniOCTAL Testing Portal.; Examine potential positive or negative changes cognition that may be associated with propofol infusion.

Trial Locations

Locations (1)

Washington University School of Medicine/Barnes-Jewish Hospital; 🇺🇸 Saint Louis, Missouri, United States